PTPRC and HIV-1 infection: Reflective of our prior (Su, et al. 2020) studies, after 12 weeks of first-generation ART administration, brain HIV-1 infection was restricted where viral RNA and DNA were below the detection limit (10 copies/106 human CD45+ cells).